# Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

> **NCT00992446** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Adult Diffuse Large B-Cell Lymphoma
- B-Cell Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin Lymphoma
- T-Cell Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Bortezomib
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **DRUG:** Rituximab
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00992446
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-02
- **Primary completion:** 2015-06-17
- **Final completion:** 2019-10-29
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992446, "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00992446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*